Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.
In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.
Physicians who treat patients with triple negative breast cancer have two new ways to predict which patients may benefit most from the well-established post-surgery treatment known as AC chemotherapy, short for adjuvant doxorubicin and cyclophosphamide.
It is a feeling that many who receive a cancer diagnosis can identify with: heartbreak and fear, followed by hopes that chemotherapy will save the day. Unfortunately, for many patients, chemo's painful side effects cause them to stop treatment prematurely.
A pacemaker-like device restored heart function in a group of cancer survivors -- mostly women with breast cancer -- who had suffered from heart failure as a result of chemotherapy treatment, a study in the Journal of the American Medical Association reports.
Drugs can be safely delivered to cancerous lymph nodes via the lymphatic system and then released inside the nodes using sound waves. Tohoku University researchers tested the treatment on mice with metastatic breast cancer and published their findings in the journal Scientific Reports.
A precise and non-toxic treatment that targets lung cancer cells at the nanoscale is able to effectively kill the cells even at a low dose.
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.
Researchers at the UCLA Jonsson Comprehensive Cancer Center have identified a new drug delivery pathway that may help stop tumor growth and keep cancer from coming back in mice.
A new study shows that diabetic retinopathy (DR), or retinal disease caused by the high blood glucose levels in diabetes mellitus, is due to the death of retinal cells because of the high levels of a pro-enzyme called lysyl oxidase propeptide (LOX-PP). This could help researchers develop specific treatments by targeting this molecule.
A treatment for psoriasis could be repurposed to treat a rare but aggressive form of youth cancer, new findings from the Garvan Institute of Medical Research suggest.
Researchers from the Tulane University School of Medicine have discovered that some cancer cells survive chemotherapy by eating their neighboring tumor cells.
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy. If scientists could put a “homing beacon” in tumors, they could attract these medicines and reduce side effects caused by the drugs acting on healthy cells.
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy after chemotherapy even when all traces of the cancer appear to have gone, according to late breaking results presented at the ESTRO 38 conference today.
For the vast majority of cancer drugs experiencing shortages over a seven-year period, a new USC research study found no statistically significant effect of shortages on chemotherapy treatment.
Of the three major subtypes of breast cancer, the «triple negative» is the most lethal: half of all breast cancer deaths are attributed to it, whereas it accounts for only about 15% of incidences of breast cancer.
Every year, 4 million new cases of cancer are diagnosed in Europe. Advances in cancer treatment sometimes come at the cost of major adverse effects, and one of the most prominent is cardiotoxicity. Myocardial toxicity affects as many as 25% of patients undergoing treatment with commonly used anticancer drugs.
A breakthrough for brain tumor drug development and personalized medicine published today in Nature Scientific Reports.
In long-term survivors of childhood cancer, cardiovascular disease is a leading cause of early death from non-cancer causes.
Multi-Walled Carbon Nanotubes is the name that is derived from their structure and walls are formed by one atom thick sheet of carbon.
Some patients with breast cancer receive chemotherapy before the tumor is removed with surgery. This approach, called 'neoadjuvant' therapy, helps to reduce the size of the tumor to facilitate breast-conserving surgery, and can even eradicate the tumor, leaving few or no cancerous cells for the surgeon to remove.
Multi-Walled Carbon Nanotubes (MWCNTs) are characterized by walls formed by a one atom thick sheet of carbon.